DelveInsight’s, “Thyroid Cancer Pipeline Insight 2024” report provides comprehensive insights about 50+ companies and 51+ pipeline drugs in Thyroid Cancer pipeline landscape. It covers the Thyroid Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Thyroid Cancer Research. Learn more about our innovative pipeline today! @ Thyroid Cancer Pipeline Outlook
Key Takeaways from the Thyroid Cancer Pipeline Report
- August 2024:- Novarits Pharmaceuticals- A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer (DTC)
- DelveInsight’s Thyroid Cancer pipeline report depicts a robust space with 50+ active players working to develop 51+ pipeline therapies for Thyroid Cancer treatment.
- The leading Thyroid Cancer Companies such as AffyImmune Therapeutics, Suzhou Zelgen Biopharmaceuticals, Bristol-Myers Squibb, Suzhou NeuPharma, AstraZeneca, Verastem Oncology, Thryv Therapeutics, Molecular Targeting Technologies, Chimerix, Codiak BioSciences, LeadArtis, Tyra Biosciences, Roche, Sichuan Kelun-Biotech Biopharmaceutical, Advenchen Laboratories, and others.
- Promising Thyroid Cancer Therapies such as Selpercatinib, Cabozantinib, Vandetanib, E7080 Capsule, Lenvatinib (DTC Cohort), Irofulven + capecitabine, XL184, AL2846 Capsule, and others.
Stay informed about the cutting-edge advancements in Thyroid Cancer Treatments. Download for updates and be a part of the revolution in cancer care @ Thyroid Cancer Clinical Trials Assessment
Thyroid Cancer Emerging Drugs
- rhTSH: Suzhou Zelgen Biopharmaceuticals
Recombinant human TSH (rhTSH) was developed to provide TSH stimulation without the requirement for THST withdrawal and the resultant metabolic disturbance, and without the drawbacks associated with the use of bovine TSH. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients with thyroid cancer.
- Nivolumab: Bristol-Myers Squibb
Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with thyroid cancer.
- RX208: Suzhou NeuPharma
RX208 is a potential “best-in-class” BRAF V600E inhibitor with a proprietary novel chemical structure that is different from other marketed BRAF inhibitors. It exhibited high bioavailability and excellent anti-tumor efficacy in preclinical studies. Early clinical data demonstrated preliminary efficacy and good safety and tolerability in patients with cancer, warranting further clinical development. The drug is currently being evaluated under Phase I/II clinical trial for the treatment of patients with thyroid cancer.
- AIC100: AffyImmune Therapeutics
AffyImmune’s lead product, AIC100, is an affinity-tuned, ICAM-1 targeted, third generation CAR T cell therapy. AIC100’s CAR has an affinity to ICAM-1 similar to the affinity between naturally-occurring T cells and their targets, which is much lower than most CARs used to date and reduces on-target off-tumor toxicities. AIC100 also expresses SSTR2 for real-time monitoring of CAR T cell distribution and activity. Preclinical studies demonstrate that AIC100 induces robust and enduring tumor eradication without toxicity-related relapse or fatality in various solid tumor models. Studies also suggest the potential for combination with anti-PD-1 therapies. The drug is currently being evaluated under Phase I clinical trial for the treatment of patients with Thyroid Cancer.
Learn more about Thyroid Cancer Drugs opportunities in our groundbreaking Thyroid Cancer Research and development projects @ Thyroid Cancer Unmet Needs
Thyroid Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
Thyroid Cancer Products have been categorized under various Molecule types such as
- Monoclonal antibody
- Small molecule
- Peptide
Discover the latest advancements in Thyroid Cancer Treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Thyroid Cancer Market Drivers and Barriers, and Future Perspectives
Thyroid Cancer Drugs and Companies
- Rosiglitazone: Exelixis
- Lenvatinib: Eisai Limited
- Ifosfamide: Merck Sharp & Dohme LLC
Scope of the Thyroid Cancer Pipeline Report
- Coverage- 7MM
- Thyroid Cancer Companies such as AffyImmune Therapeutics, Suzhou Zelgen Biopharmaceuticals, Bristol-Myers Squibb, Suzhou NeuPharma, AstraZeneca, Verastem Oncology, Thryv Therapeutics, Molecular Targeting Technologies, Chimerix, Codiak BioSciences, LeadArtis, Tyra Biosciences, Roche, Sichuan Kelun-Biotech Biopharmaceutical, Advenchen Laboratories, and others.
- Thyroid Cancer Therapies- Selpercatinib, Cabozantinib, Vandetanib, E7080 Capsule, Lenvatinib (DTC Cohort), Irofulven + capecitabine, XL184, AL2846 Capsule, and others.
- Thyroid Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Thyroid Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Thyroid Cancer Pipeline on our website @ Thyroid Cancer Drugs and Companies
Table of Content
- Introduction
- Executive Summary
- Thyroid Cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Thyroid Cancer– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- rhTSH: Suzhou Zelgen Biopharmaceuticals
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Nivolumab: Bristol-Myers Squibb
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- AIC100:Affyimmune Therapeutics
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Thyroid Cancer Key Companies
- Thyroid Cancer Key Products
- Thyroid Cancer- Unmet Needs
- Thyroid Cancer- Market Drivers and Barriers
- Thyroid Cancer- Future Perspectives and Conclusion
- Thyroid Cancer Analyst Views
- Thyroid Cancer Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/